These consensus statements were developed by the European Association of Urology (EAU) and the European Society for Medical Oncology (ESMO) and are published simultaneously in European Urology and Annals of Oncology.
Introduction
Bladder cancer is the 10th most common form of cancer globally, with 549 393 new cases and 199 922 bladder cancer-related deaths estimated in 2018 [1] . It is around four times more common in men, where it is the sixth most common cancer and the ninth leading cause of cancer death. The incidence of bladder cancer varies globally, with the highest rates in men and women reported in Southern and Western Europe and North America, which appears to reflect the prevalence of tobacco smoking, the main risk factor for bladder cancer [1, 2] .
Various oncology and urology societies, including the European Society for Medical Oncology (ESMO) [3] and the European Association of Urology (EAU) [4, 5] , all produce Clinical Practice Guidelines (CPGs) that provide guidance to health care professionals (HCPs) regarding the optimal strategies for diagnosis, treatment and follow-up of patients with bladder cancer based on the latest evidence and expert opinion. However, evidence is limited and/or conflicting in some areas of advanced and variant bladder cancer management, and the optimal approach remains controversial, warranting further discussion and clarification. For example, the pathological features and prognosis of bladder cancer with variant histologies differ from pure urothelial bladder cancer, and evidence regarding response to systemic therapy in these variant histologies is scarce and divergent [6] . In addition, although efforts have been made to identify molecular subtypes of bladder cancer and to link these with clinical-pathological features and treatment response [7] [8] [9] [10] , there is no consensus regarding the number of subtypes that can be defined and available evidence to link subtypes with response to specific therapies is conflicting [11] .
In terms of disease management, although transurethral resection of the bladder tumour (TURBT) is the initial treatment of choice for non-muscle-invasive bladder cancer (NMIBC), with subsequent treatment tailored according to risk stratification [3, 4] , TURBT followed by concurrent chemoradiation (i.e. trimodality bladder preservation treatment) is also an option for muscle-invasive bladder cancer (MIBC) in patients considered medically unfit for surgery and in those wishing to avoid radical surgery [3, 4] . However, patient selection for bladder-sparing strategies varies globally and there are no uniform criteria on which to base these decisions. The optimal chemotherapy regimen to use as part of trimodality bladder preservation treatment has also not been defined [12] .
Radical cystectomy with extended lymphadenectomy is considered the standard treatment of MIBC, and although neoadjuvant therapy has been used in this setting for several decades, the role of adjuvant therapy remains controversial [3, 5, 12] . The benefit of adding (neo)adjuvant chemotherapy to radical cystectomy and node dissection in oligometastatic disease (OMD) is also unknown. In the metastatic setting, cisplatin-based chemotherapy remains the first-line treatment of choice for patients considered fit enough to receive this regimen, but the preferred approach for cisplatin-ineligible patients is less clear [5, 12] . Options include various carboplatin-based regimens or the immune checkpoint inhibitors (ICIs), pembrolizumab or atezolizumab, although approvals of these ICIs are based on data from single-arm, phase II trials [13, 14] , and their use in Europe is currently restricted to programmed death-ligand 1 (PD-L1)-positive patients with different companion diagnostics and cut-offs used for each ICI. In terms of second-line treatment, various chemotherapy options have been evaluated but results are highly variable [5] . Three ICIs (pembrolizumab, atezolizumab and nivolumab) are approved in this setting in Europe (durvalumab and avelumab are also approved in the United States but not in Europe), although only pembrolizumab has demonstrated an overall survival (OS) benefit versus chemotherapy in a phase III randomised controlled trial [15] . There are no data to provide guidance regarding the optimal treatment sequencing approach for ICIs and chemotherapy.
Finally, although there is no evidence to suggest that regular follow-up after definitive treatment is associated with any survival benefit in patients with bladder cancer, most guidelines recommend regular follow-up, but no high-level, evidence-based follow-up protocol exists.
Collectively, these and other topics represent points in the bladder cancer care pathway where evidence is limited/conflicting and thus where a variation in practice may exist. Given this, the aim of this consensus-finding project was to gain insights from a multidisciplinary group of experts in order to produce consensus statements that would further guide HCPs on selected clinically relevant topics. It was anticipated that these consensus statements would underpin clinical practice guideline recommendations produced by existing society guidelines and facilitate an optimal approach to the diagnosis, treatment and follow-up of patients with advanced and variant bladder cancer.
Methods
In 2018, the EAU and ESMO formed a collaboration to produce consensus statements for the management of bladder cancer. A project steering committee was established, which comprised a multidisciplinary panel of 13 experts from EAU and ESMO, including two chairpersons (J.A. Witjes and A. Horwich) . This steering committee worked together to develop a series of statements, based on their knowledge of the field, relating to potential management strategies for patients with advanced and variant bladder cancer. They were asked to focus on specific situations where good-quality evidence is lacking or where available evidence is conflicting. A systematic literature review was not conducted. Statements were divided into six discrete topic areas with members of the steering committee appointed to chair each of these working groups as follows: All final statements were entered into DelphiManager (a bespoke online Delphi tool, written in C# using WebForms and a MySQL backend) [16] . The resulting Delphi survey was distributed to key stakeholder groups including (i) Urologists, (ii) Oncologists (including Medical and Radiation Oncologists) and (iii) 'Others' (consisting of Radiologists, Pathologists, Specialist Nurses, Clinical Oncologists and Specialists in Nuclear Medicine). Participants were purposefully sampled by contacting professional societies, including the EAU, ESMO, the American Society of Clinical Oncology (ASCO), American Urological Association (AUA), European Society for Radiotherapy and Oncology (ESTRO), European Forum for Primary Care (EFPC), European Association of Urology Nurses (EAUN), Canadian Urological Association (CUA), International Society of Urological Pathology (ISUP), Urological Society of Australia and New Zealand (USANZ), European Society of Urogenital Radiology (ESUR), Urological Association of Asia (UAA), American Society for Radiation Oncology (ASTRO), EAU bladder cancer guideline panels (both MIBC and NMIBC panels) and the EAU Section of Oncological Urology (ESOU). Consent to participate was implied by registering and completing the questionnaire. All HCPs were asked to rate their strength of agreement with each statement on a scale of 1 (strongly disagree) to 9 (strongly agree). An additional option of 'unable to score' was included to allow participants to refrain from rating any statements where they felt that they had insufficient expertise to do so. Two iterative rounds of the Delphi survey were conducted. In the first round, participants were also encouraged to propose additional statements, which were reviewed for relevance by the chairpersons. In the second round, participants were reminded of their own scores from round 1 and were also provided with a summary score from each of the three stakeholder groups. From this, participants had the opportunity to revise or retain their original scores. None of the statements were amended between rounds.
Descriptive statistics were used to summarise the results of each survey round, which included calculating the percentage of participants who scored each statement as 1-3 (disagree), 4-6 (equivocal), 7-9 (agree) and 'unable to score'. Results were summarised according to the three stakeholder groups described above. After the final survey round, the level of agreement for each statement was assessed for all three stakeholder groups separately, with consensus defined a priori as:
• Item scored as agree (7) (8) (9) by 70% of participants AND disagree (1-3) by 15%, OR • Item scored as disagree (1-3) by 70% of participants AND agree (7-9) by 15%.
Results of this analysis showed that consensus was reached for relatively small (28%) number of statements. On further review, the steering committee felt that these results might have been affected by some participants who provided a score of 4-6 (i.e. equivocal) instead of selecting 'unable to score' in cases where they had insufficient expertise to adequately assess the statement. To address this, a second analysis was conducted using the same consensus rules as described above but where the analysis was restricted to specific stakeholder group(s) considered to have adequate relevant expertise relating to the specific statement. Stakeholder group(s) considered as having adequate relevant expertise for each statement were defined by the chairmen before this second analysis.
Final results were tabulated according to the three stakeholder groups with a consensus level defined for each statement which considered both of the analyses conducted as follows:
• Level 1: A priori consensus threshold met across all three stakeholder groups (i.e. original consensus analysis).
• Level 2: A priori consensus threshold not met across all three stakeholder groups but met when analysis restricted to most relevant stakeholder group(s).
• Level 3: A priori consensus threshold not met.
A subsequent review of the results was carried out by the steering committee in order to identify statements where a consensus was almost reached. These statements were prioritised for further review and discussion as part of a consensus conference meeting held on 8 November 2018 in Amsterdam, The Netherlands.
All HCPs who completed the survey were invited to attend the consensus conference. However, based on limited availability for a face-to-face meeting, additional HCPs also considered as important stakeholders in the management of bladder cancer were invited, with all attending experts allocated to one of the six working groups defined earlier. During the conference, statements prioritised for further review were discussed by each of the working groups during parallel breakout sessions. This included a review of related supporting and/or conflicting evidence informing each statement, and revision of these statements, where necessary. The final statements from each working group were then presented to the entire expert panel for further deliberation and amendment. Finally, the expert panel was asked to rate its strength of agreement with each of the revised statements using the same scale applied during the Delphi survey using online voting software (https://www.polleverywhere.com/, 15 October 2019, date last accessed). All voting was conducted using individual smartphone devices and was anonymous. Panel members could abstain from voting in cases where they had insufficient expertise to adequately assess the statement (which negated the requirement for an 'unable to score' option).
Results from the Delphi survey and consensus conference are described in this article. For statements revised and re-assessed during the consensus conference, the updated results as well as a summary of evidence and/or the rationale for statement revisions are also included. The authors of this article include all Delphi survey participants, consensus conference attendees and other individuals who provided significant contributions to this project, all of whom have reviewed and approved the final manuscript.
Results
The steering committee generated 115 statements relating to the management of advanced and variant bladder cancer for assessment as part of the Delphi survey; after round 1, an additional statement was added for assessment during round 2.
Overall, 221 HCPs were invited to participate in the Delphi survey, and of these, 113 registered and completed at least some of the survey (scores for completed questions were retained); 106 completed round 1 and 97 completed round 2 of the survey. A summary of participants who completed the Delphi survey according to speciality is shown in In the Delphi survey, the initial (a priori) analysis resulted in a level 1 consensus for 18 (16%) statements in round 1 and 33 (28%) statements in round 2, with inclusion of statements reaching level 2 consensus increasing this to 49 (42%) statements after round 2. At the consensus conference meeting, 27 statements were amended/presented for voting and 22 (81%) achieved consensus among the group, giving a total of 71 statements that achieved consensus throughout the whole process.
The following section provides detailed results according to each of the six topic areas, including:
1. All Delphi survey statements developed by the steering committee for each topic area. 2. Delphi survey results for each of these statements highlighted according to the consensus level reached for each statement, as shown in Table 2 . 3. All statements generated by the consensus conference working groups for each topic area. 4. Consensus conference voting results for each of these statements. 5. A summary of expert panel discussions from the consensus conference to support these statements.
Strategies for variant histologies
The Delphi survey included 14 proposed statements regarding the management of bladder cancer with variant histologies, including the role of different treatment approaches such as radical cystectomy, lymphadenectomy, radiotherapy, chemotherapy and checkpoint inhibitor therapy, in this setting (Table 3) . According to the Delphi survey results, five of the 14 statements reached consensus among all stakeholder groups (Table 3) . For the remaining statements, seven were prioritised and four new/modified statements were presented at the consensus conference for further discussion and voting. Results from the Table 2 )
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1. T1 high-grade bladder urothelial carcinoma (established after complete TURBT and/or re-TURBT) with micropapillary variant should be treated with immediate radical cystectomy Table 2 )
45)
32)
9. Muscle-invasive pure adenocarcinoma of the bladder should be treated with primary radical cystectomy and lymphadenectomy Table 2 for details of consensus level criteria). Statements indicated in bold were subsequently reviewed at the consensus conference with revised statements and voting shown in Table 4 and supporting text is provided below. [17] . The proportion of carcinoma with micropapillary features can vary significantly, with a larger component being associated with a worse prognosis [18] . Micropapillary variant is strongly associated with lymphovascular invasion and metastasis to the lymph nodes, and pT1 bladder cancer with micropapillary variant is often upstaged to more advanced stages [18] . Its pathological diagnosis on a transurethral resection (TUR) specimen is subject to both underreporting by pathologists and understaging due to intrinsic biological properties of the variant histology in addition to the normal risk of understaging with TURBT. In one study, after adjustment for the effects of pathological stage, only the presence of micropapillary variant, but not that of squamous or sarcomatoid differentiation, was associated with a worse survival [19] . Given the poor response rate (RR) to intravesical bacillus Calmette-Guérin (BCG) administration, the current standard of care treatment of most cT1 urothelial carcinomas of the bladder, a recent study evaluated the potential benefits of early (immediate) radical cystectomy for cT1 micropapillary variant urothelial carcinoma [20] . In this retrospective, comparative design study, which included 72 patients with cT1 micropapillary bladder cancer, 40 patients received primary intravesical BCG and 26 underwent upfront radical cystectomy. Of those who received intravesical BCG, 75%, 45% and 35% experienced disease recurrence, progression and lymph node metastasis, respectively, during a median follow-up of 67.5 months. However, patients treated with upfront radical cystectomy had improved survival compared with those treated with BCG (5-year disease-specific survival [DSS] of 100% versus 60%, P ¼ 0.006) and those who underwent delayed radical cystectomy after disease recurrence (5-year DSS of 62%, P ¼ 0.015). Patients in the delayed radical cystectomy group also had higher rates of pT3 disease (25% versus 0%, P ¼ 0.04) and overall pathological disease progression (pT2 or greater, or nodal disease: 40% versus 27% in the upfront radical cystectomy group) [20] .
Given the above, the panel decided to add the recommendation for concomitant pelvic lymph node dissection (PLND) to the original statement regarding the treatment of T1 high-grade bladder urothelial carcinoma with micropapillary variant to read as follows:
Statement 1: T1 high-grade bladder urothelial carcinoma with micropapillary histology (established after complete TURBT and/or re-TURBT) should be treated with immediate radical cystectomy and lymphadenectomy. Level of consensus: 86% Agree, 14% disagree (29 voters).
2. Treatment of high-grade bladder urothelial carcinoma with plasmacytoid, sarcomatoid, squamous, glandular or nested variant histologies. Understaging at the time of TUR is more frequent in urothelial carcinomas with variant histology compared with pure urothelial carcinomas and has been shown to be closely associated with a lower median OS (1.4 versus 10.6 years, P < 0.001) [21] . Therefore, immediate radical cystectomy for better staging and definitive treatment purposes seems to be an appropriate option. However, the resulting statement shown below failed to reach consensus among the panel, and this is likely due to the low level of evidence currently available to support this approach in urothelial carcinomas with variant histology.
Statement 2: T1 high-grade bladder urothelial carcinoma (established after complete TURBT and/or re-TURBT) with plasmacytoid, sarcomatoid, squamous, glandular or nested variant should be treated with immediate radical cystectomy and concomitant lymph node dissection. Level of consensus: 48% Agree, 39% disagree, 13% equivocal (31 voters).
3. Treatment of MIBC with micropapillary or plasmacytoid variant, or with squamous or glandular differentiation. Only limited evidence is available regarding the added benefit of neoadjuvant chemotherapy for bladder cancers with variant histology due to a lack of prospective studies [22] . In one retrospective population-based study, Vetterlein et al. [6] evaluated the added benefit of neoadjuvant chemotherapy administration in patients with muscle-invasive urothelial carcinoma harbouring variant histologies (369 patients underwent neoadjuvant chemotherapy followed by radical cystectomy whereas 1649 patients underwent upfront radical cystectomy). Patients with neuroendocrine tumours benefited most from neoadjuvant chemotherapy administration, as evidenced by better OS (hazard ratio 0.49; 95% confidence interval 0.33-0.74; P ¼ 0.01) and lower rates of non-organ-confined disease at the time of radical cystectomy (41.6% versus 76.4%). For tumours with micropapillary differentiation, sarcomatoid differentiation or adenocarcinoma, neoadjuvant chemotherapy decreased the rates of non-organ-confined disease but did not impact OS [6] . The revised statement proposed was as follows:
Statement 3: Muscle-invasive bladder urothelial carcinoma with micropapillary or plasmacytoid variant, or with squamous or glandular differentiation, should be treated with neoadjuvant chemotherapy followed by radical cystectomy and concomitant lymphadenectomy. Level of consensus: 63% Agree, 12% disagree, 24% equivocal (33 voters).
4. The role of adjuvant radiotherapy for the treatment of MIBC with variant histologies. Patients with urothelial carcinoma with squamous and/or glandular differentiation are more likely to have pT3-T4 tumours (70% versus 38%, P < 0.0001) and pNþ disease (20% versus 15%, P ¼ 0.05) than those with pure urothelial carcinoma, confirming the observation that they are more likely to die of local than distant metastatic disease [23] . This would provide a strong argument to consider improving local control by adjuvant radiotherapy especially in cases of positive margins at areas amenable for radiotherapy [24, 25] .
Statement 4: Adjuvant radiotherapy (with or without radiosensitising chemotherapy) is a standard treatment of patients with muscle-invasive urothelial carcinoma with variant histologies.
Level of consensus: 41% Agree, 37% disagree, 21% equivocal (29 voters).
The role of prognostic molecular markers in MIBC
The Delphi survey included 21 statements relating to the role of prognostic molecular markers in MIBC, which included 11 statements on the value of genetic profiling and specific mutation patterns or RNA subtypes when making therapeutic decisions, and 10 statements covering the value of tumour mutation burden, microsatellite instability, neutrophil-to-lymphocyte ratio (NLR), albumin and lactate dehydrogenase (LDH) when making treatment decisions regarding cystectomy, chemotherapy or immunotherapy (Table 5 ). According to the Delphi survey results, 10 out of these 21 statements achieved consensus, four among all stakeholder groups and six among relevant stakeholder groups only (Table 5 ). For the remaining statements, three controversial topics were identified and prioritised, and related statements were discussed and reassessed at the consensus conference. Results from the consensus panel scoring of the relevant statements are shown in Table 6 and supporting text is provided below.
1. Before prescribing checkpoint inhibitor therapy, do we need to identify molecular subtypes based on RNA analysis? The molecular classification of bladder cancer has gained momentum in recent years and is still under development. Several attempts have been made, and there is still no agreement regarding how many subgroups can be established and defined. All of these molecular classifications have been updated in the last 4 years, with The Cancer Genome Atlas (TCGA) and the Lund classifications the most recently updated [7, 26] . Clearly, different subtypes exist, and among them, two main subtypes can be distinguished: luminal and basal. According to their molecular appearance, the urothelial carcinomas react differently to different therapies. However, it is important to consider that TCGA data provide no information regarding response to subsequent treatment after cystectomy for MIBC. There is only one report based on retrospective data from patients receiving different types of neoadjuvant chemotherapy where RNA subtypes have been linked to outcome [27] . For immunotherapy, conflicting findings have been reported regarding response enrichment in luminal II and basal subtypes [28] . Lack of consensus on the description of the different RNA subtypes is also a problem. Data linking responses of atezolizumab with the 'genomically unstable' subgroup of the Lund classification is discordant with previously reported findings for the luminal II subtype [29] .
Given the currently available evidence, the panel agreed that RNA subtypes are not needed when ICIs are prescribed because it is too early and requires further validation. The original statement from the Delphi survey was therefore retained and a consensus regarding this statement was reached by the expert panel, as shown below.
Statement 1: Before prescribing checkpoint inhibitor therapy, RNA subtypes always need to be identified. Level of consensus: 3% Agree, 91% disagree, 6% equivocal (31 voters Table 2 )
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1. In patients with metastatic disease, genetic profiling should never be done Table 2 )
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12. Before prescribing a checkpoint inhibitor, TMB always needs to be assessed Table 2 for details of consensus level criteria). Statements indicated in bold were subsequently reviewed at the consensus conference with revised statements and voting shown in Table 6 . A, agree; D, disagree; DDR, DNA damage response; E, equivocal; ERCC, DNA excision repair protein; FGFR3, fibroblast growth factor receptor 3; HER2, human epidermal growth factor receptor 2; LDH, lactate dehydrogenase; MIBC, muscle-invasive bladder cancer; MSI, microsatellite instability; NLR, neutrophil-to-lymphocyte ratio; On, Oncologists; RNA, ribonucelic acid; TMB, tumour mutation burden; TSC1, tuberous sclerosis complex 1; U, unable to respond; Ur, Urologists. [30] and other nonurological malignancies. The use of the NLR as a predictive tool is derived from studies using chemotherapy in oesophageal, gastric and colorectal cancers. Data have also emerged for NLR as a potentially predictive biomarker in patients receiving immunotherapy for melanoma, lung cancer and renal cell carcinoma. In a recent pooled analysis of 21 studies analysing the prognostic role of NLR in bladder cancer, the authors correlated elevated pre-treatment NLR with OS, recurrence-free survival and DSS in patients with localised disease and in those with metastatic disease [31] . In contrast, in a recent secondary analysis from the Southwest Oncology Group (SWOG) 8710 trial which assessed the role of neoadjuvant chemotherapy in MIBC, the authors could not demonstrate any correlation between NLR and OS (prognostic) or the OS benefit from neoadjuvant chemotherapy (predictive) [32] . After considering the available data, the panel agreed that before radical cystectomy or chemotherapy, NLR does not need to be assessed. Although it is easy to do, we require prospective data before this can be used to drive or change treatment decisions.
Statement 2:
Before radical cystectomy or chemotherapy, the NLR does NOT need to be assessed. Level of consensus: 97% Agree, 3% disagree (31 voters).
3. In patients with metastatic disease, do we need to assess LDH and/or serum albumin? No strong data exist regarding the value of albumin or LDH as prognostic factors in metastatic bladder cancer. In Bajorin's risk factor analysis in patients with previously untreated metastatic bladder cancer, neither LDH nor albumin was identified as significant risk factors in multivariate analysis despite being significant in the univariate analysis [33] . However, as albumin and LDH are easy to measure in peripheral blood and are already validated in other cancers, these parameters are being used in daily clinical practice. For patients treated with secondline chemotherapy, haemoglobin, performance status (PS) and liver metastasis are recognised prognostic factors [34] . However, in a pooled analysis of data from 10 phase II trials evaluating various different therapies, the addition of albumin to these already-established prognostic factors emerged as significant [35] . A recent meta-analysis has also confirmed the prognostic role of LDH in urological cancer [36] .
After considering the available data, working group 2 proposed that LDH and/or serum albumin should always be measured in patients with metastatic disease as a general prognostic marker of outcome, not relating to bladder cancer specifically but rather as a prognostic cancer marker. Although there was some agreement by the expert panel for this statement, it failed to reach the consensus threshold.
Statement 3:
In patients with metastatic disease, always measure the LDH and/or serum albumin as general prognostic markers of patient outcome. Level of consensus: 65% Agree, 16% disagree, 19% equivocal (31 voters).
Bladder preservation strategies
The Delphi survey included 19 statements relating to bladder preservation strategies, including patient selection, chemoradiation and radiosensitisers, adjuvant therapy and PLND (Table 7 ). An additional statement was added to this category following results of round 1 of the survey.
According to the Delphi survey results, nine of the 20 statements reached consensus, six among all stakeholder groups and three among relevant stakeholder groups only (Table 7) . For the remaining statements, nine were prioritised for further discussion and revision. Results from the consensus panel scoring of the new/revised statements are shown in Table 8 and supporting text is provided below.
1. Patient selection for bladder preservation strategies. Patient selection depends on the organisation of the health care system per country in general and per department in particular. Specialist bias and available therapeutic options can and will influence treatment of cancer patients. For example, despite the known benefits of neoadjuvant chemotherapy, its use is strongly associated with communication with and referral to a medical oncologist. In colorectal cancer, collaboration between surgeons and oncologists has been shown to improve both all-cause and cancer-specific survival [37] . The role of the specialist nurse, Table 2 )
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14. The preferred radiosensitiser is BCON Table 2 for details of consensus level criteria). Statements indicated in bold were subsequently reviewed at the consensus conference with revised statements and voting shown in Table 8 which also differs according to the country and department, has also been shown to improve patient quality of life, is costeffective and lowers the workload of the physician [38] .
Statement 1:
Candidates for curative treatment, such as cystectomy or bladder preservation, should be clinically assessed by at least an oncologist, a urologist and a neutral health care professional such as a specialist nurse. Level of consensus: 83% Agree, 6% disagree, 12% equivocal (34 voters).
2. Chemoradiation for inoperable, locally advanced MIBC. For MIBC, multiple studies have shown that the addition of chemotherapy to radiotherapy improves local control and survival rates compared with radiotherapy alone, and also results in good longterm bladder function and low rates of salvage cystectomy [39] [40] [41] [42] . The addition of gemcitabine, cisplatin (NCIC), carbogen/ nicotinamide (BCON) or 5-fluorouracil (5FU)/mitomycin C (MMC) (BC2001) to radiotherapy have all either been compared with radiotherapy alone or have single arm data and extensive use in clinical practice [39] [40] [41] [42] .
Statement 2: Chemoradiation should be given to improve local control in cases of inoperable locally advanced tumours. Level of consensus: 85% Agree, 3% disagree, 12% equivocal (32 voters).
Radiosensitisers.
As there are no comparative data available for the use of radiosensitisers in MIBC, there was consensus among the expert panel not to recommend any specific radiosensitiser in case of chemoradiation therapy. Obviously, the patient needs to be fit enough to undergo chemotherapy. If not, radiotherapy alone is an option to be discussed with the patient as a palliative treatment strategy.
Statement 3:
In case of bladder preservation with radiotherapy, combination with a radiosensitiser is always recommended to improve clinical outcomes, such as cisplatin, 5FU/MMC, carbogen/nicotinamide or gemcitabine. Level of consensus: 100% Agree, 0% disagree (29 voters).
Pelvic lymph nodes.
According to several large cystectomy series, micrometastases in the pelvic lymph nodes are found in 25%-44% of patients with MIBC. For patients receiving chemoradiation, a group who often have a worse prognosis, this might be even higher. In order to minimise bowel toxicity for patients with cN0 disease, many centres do not target pelvic lymph nodes. However, with modern intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) techniques, this is now much more feasible. Surprisingly, findings from the large BC2001 and BCON trials, which included radiotherapy confined to the bladder only, did not report high rates of lymph node relapse (typically <10%) as might have been expected from surgical pathological staging on cystectomy, suggesting that chemoradiation partially eradicates pelvic lymph node micrometastases [43] . However, this was not confirmed in a chemoradiation trial comparing radiotherapy to the whole pelvis versus the bladder (tumour site) alone. Among complete responders, the incidence of pelvic lymph node recurrence was 15.8% and 17.6%, respectively [44] . Consequently, given the current literature, no consensus could be reached regarding whether or not to carry out a PLND in bladder preservation strategies. 6. Radiotherapy dosing. Brachytherapy for MIBC is not widely carried out and data are therefore limited to highly selected patients in centres with a particular interest in this field. So far, only retrospective studies have been carried out, which have included a wide variation in patient and tumour characteristics. In the majority of patients who received brachytherapy, this was preceded by EBRT [46] . Moreover, it is an invasive procedure that requires surgical catheter placement. As prospective or randomised controlled trials on brachytherapy are lacking, there was consensus among the expert panel not to recommend brachytherapy for MIBC. There was also a consensus not to recommend dose escalation by IMRT based on limited early results [47] . A UK-based randomised trial (RAIDER) addressing the potential value of dose escalation has just completed accrual and will provide further insights on this topic.
Statement 6: Dose escalation above standard radical doses to the primary site in case of bladder preservation, either by IMRT or brachytherapy, is not recommended. Level of consensus: 86% Agree, 7% disagree, 7% equivocal (28 voters).
The role of treatment of curative intent in OMD
OMD is generally defined as occurrence of 5 metastases and may be found synchronous with the primary tumour or as a metachronous recurrence. There has been much biological research regarding how OMD may arise as an early phase in the metastatic cascade, and on how this might be distinguished from polymetastatic disease [48] . Although the finding of OMD may offer hope of cure, for the responsible clinician, an important consideration is the avoidance of toxicities associated with radical therapies in a palliative setting. There are few published series about the radical treatment of OMD in urothelial cancers; hence, no guidelines have addressed its management [49] . Thus, questions need to be addressed, at least in part, by reference to other cancers or other disease stages. For example, a multicentre review of radical surgery for 5206 cases of lung metastases reported a 5-year survival rate of 36%, encouraging the belief that an early stage of metastasis exists which may be very limited in extent and thus curable by radical treatment [50] . Important prognostic factors in this series included whether the OMD was solitary and whether the recurrent OMD occurred a long time (>36 months) after treatment of the primary tumour. Similarly, in non-small cell lung cancer, findings from a systematic review and pooled analysis showed that among 110 patients who had an adrenalectomy for an isolated adrenal metastasis, OS was shorter for those with synchronous versus metachronous metastasis (12 versus 31 months, respectively; P ¼ 0.02) [51] . Similarly encouraging series based on the radical treatment of metastases with stereotactic radiotherapy have also been reported.
This Delphi survey included 21 statements relating to the role of treatment of curative intent in OMD, including the number of metastatic sites consistent with possible cure, the curability of different OMD organ locations, synchronous versus metachronous OMD, the question of delayed restaging and staging technology, use of adjuvant chemotherapy, choice of radical OMD therapy, extent of primary surgery and the sequence of treating synchronous presentations (Table 9) .
According to the Delphi survey results, four of the 21 statements reached consensus across all stakeholder groups (Table 9 ). For the remaining statements, three controversial topics were identified and prioritised, and related statements were discussed and reassessed at the consensus conference. Results from the consensus panel scoring of the relevant statements are shown in Table 10 and supporting text is provided below.
Number of metastatic sites consistent with possible cure.
Results from the Delphi survey showed that there was a consensus among participants that the presence of more than two metastatic sites should discourage attempted cure, that liver and bone are adverse prognostic sites and that longer time to metachronous OMD recurrence is associated with a more favourable outcome. However, there was no consensus regarding whether cure should be attempted for patients with one or two metastatic sites.
Based on results from prospective phase III trials, 10% of patients with urothelial cancer and visceral metastases survive 5 years after chemotherapy [52] . Prognostic factors include PS, laboratory parameters (albumin, haemoglobin, leukocyte count or CRP), visceral metastasis and number of metastatic sites. Number of metastatic sites was identified as an independent predictive factor for survival with the best prognosis seen in those with a single metastatic site only [53] .
Although there is only low-level evidence, encouragingly long survival times have been reported for patients with favourable prognostic factors after the combination of systemic chemotherapy and local treatment (radical cystectomy, metastasectomy). A retrospective study of 44 patients treated across 15 German centres reported a 5-year survival rate of 28% [54] , and in a series of 42 patients from Japan treated by metastasectomy, in patients with solitary nodal or lung metastasis (15 patients), the median OS reached 81 months [55] . A small series from Korea [49] also supported these conclusions. As summarised in a recent collaborative systematic review in metastatic bladder cancer [56] , the beneficial role of metastasis surgery remains unproven by a prospective trial but may be considered in those with low volume Table 2 )
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1. In patients with one metastatic site, cure is still possible 18 disease (especially pelvic node disease) and ideally in those with chemo-sensitive disease.
Statement 1:
In a minority of patients with one metastatic lesion, cure is possible after radical treatment. Level of consensus: 91% Agree, 6% disagree, 3% equivocal (31 voters).
2. The role of positron emission tomography-computed tomography in staging of OMD. To minimise the risk of overtreatment, patients with OMD should be restaged using the most sensitive imaging technique available. 18F-fluoredeoxyglucose (FDG)-positron emission tomography (PET)-computed tomography (CT) scanning is generally more sensitive than CT in urothelial cancer, although its use around the bladder is compromised by the urinary excretion of the isotope and its use in staging of the primary tumour currently lacks sufficient evidence to support its recommendation. However, in a staging study of 42 patients before cystectomy, FDG-PET-CT detected metastases in seven patients who showed no evidence of disease on CT and bone scans [57] . A published review of six series also found a high diagnostic accuracy for metastatic lesions using FDG-PET-CT [58] , and a recent review from The National Institutes of Health, Bethesda, USA, concluded that FDG-PET-CT was the optimal technology in this setting [59] .
Statement 2: PET-CT scanning should be included in OMD staging when considering radical treatment. Level of consensus: 88% Agree, 3% disagree, 9% equivocal (32 voters).
3. The role of downstaging chemotherapy in OMD. There are no direct comparative studies regarding whether or not to combine systemic therapy with local therapy for urothelial OMD. However, outcomes research on OMD in other tumours emphasises the high risk of recurrence after local treatment alone. There is evidence to support the use of systemic chemotherapy as a component of treatment of high-risk (muscle-invasive) primary bladder cancer. Neoadjuvant chemotherapy with cisplatin/methotrexate/vinblastine was associated with a 16% reduction in mortality risk. An overview of adjuvant chemotherapy trials has also suggested a reduction in mortality risk by over 20%, with a particular benefit seen in higher-risk (i.e. node-positive) cases [60] .
Statement 3: Radical treatment of OMD should be accompanied by adjuvant or neoadjuvant systemic therapy. Level of consensus: 72% Agree, 6% disagree, 22% equivocal (32 voters).
ICIs in urothelial bladder cancer
The Delphi survey included 20 statements relating to ICIs in urothelial bladder cancer, including patient selection, timing and duration of ICI therapy (Table 11) . According to the Delphi survey results, nine of the 20 statements reached consensus, five among all stakeholder groups and four among relevant stakeholder groups only (Table 11 ). Table 2 )
45)
32)
Others (n 5
20) D (%) E (%) A (%) U (n) D(%) E(%) A(%) U(n) D(%) E (%) A (%) U (n)
20. In case patients with visceral OMD are offered a radical cystectomy, a standard LND should be offered (pelvic lymph nodes up to crossing of ureter with common iliac vessels) Table 2 for details of consensus level criteria). Statements indicated in bold were subsequently reviewed at the consensus conference with revised statements and voting shown in Table 10 .
A, agree; CT, computed tomography; D, disagree; E, equivocal; LND, lymph node dissection; O, others (includes specialities in Nuclear Medicine, Pathology, Radiology, Specialist Nurse, Clinical Oncology); On, Oncologists; OMD, oligometastatic disease; PET, positron emission tomography; U, unable to respond; Ur, Urologists.
For the remaining statements, four key topics were prioritised and related statements were discussed and reassessed at the consensus conference. Results from the consensus panel scoring of the corresponding new/revised statements are shown in Table 12 and supporting text is provided below.
1. Pseudo-progression with ICIs. Pseudo-progression, defined as tumour growth followed by tumour response after initiation of ICI therapy, has been described in melanoma [61] . It is thought that the initial immune infiltration may make the tumour appear radiologically larger without defining treatment failure. It tends to occur at the start of therapy and can confuse clinical assessment. Progression of disease is the commonest radiological outcome with single-agent ICI therapy in urothelial cancer [13, 15, 62] . However, there is a lack of data to support the hypothesis that a proportion of these tumours can recede after initial progression, and the consensus panel agreed that pseudo-progression has not been demonstrated in urothelial cancer. The biology of urothelial cancer and melanoma are distinct, as are responses to ICI therapy. Treatment with ICIs beyond progression in the hope of pseudo-progression may therefore be counterproductive in urothelial cancer.
Statement 1: Pseudo-progression has not been demonstrated in urothelial cancer. Level of consensus: 89% Agree, 11% equivocal (28 voters).
The role of PD-L1 biomarkers to guide the use of ICI therapy.
There are five different ICI cancer drugs currently available, all of which have a different companion diagnostic to measure PD-L1 (142-atezolizumab, 288-nivolumab, 263-durvalumab, 7310-avelumab, 223-pembrolizumab) [63] . Each has a different antibody and method of measurement (immune cell versus tumour cell expression, different percentage cut points, Daco versus Ventana technology). For these reasons, positivity varies between 20% and 60% in the platinum-refractory setting for the five different methods. The biomarkers are also inconsistent in the platinumrefractory metastatic setting and appear more prognostic than predictive [15, 62] . None can be reliably used to select treatment due to their lack of sensitivity and specificity [63] .
In the front-line, cisplatin-ineligible setting, only data from single-arm trials of atezolizumab and pembrolizumab are in the public domain [13, 14] , and again, the data appear inconsistent. However, the European Medicines Agency (EMA) has changed their scope of use to restrict them to only PD-L1-positive patients in this setting. This must be related to publicly unavailable data suggesting that the biomarker is predictive. It suggests that the biomarker is effective for selecting patients in the front-line, cisplatin-ineligible setting, unlike the platinum-refractory setting. The reasons for this are unclear.
Statement 2:
In contrast to the first-line setting, the PD-L1 biomarker is not useful for selecting patients for immunotherapy in platinum-refractory metastatic urothelial cancer. Level of consensus: 81% Agree, 4% disagree, 15% equivocal (28 voters).
3. The role of chemotherapy in cisplatin-ineligible, PD-L1-positive patients with metastatic urothelial carcinoma. Although ICIs are associated with long-term, durable remissions as a first-line treatment of cisplatin-ineligible, PD-L1-positive patients with metastatic urothelial carcinoma, RRs, progression-free survival and OS have not been proven to be superior to carboplatin-based chemotherapy [13, 14] . Chemotherapy is associated with significant RRs in this setting. Data from randomised phase III trials of ICIs in this setting will be available soon and, as results are unpredictable, it seems prudent to wait until these data are available before definitive decisions are made.
Statement 3:
Carboplatin-based chemotherapy remains a viable first-line treatment option in cisplatin-ineligible, PD-L1-positive patients with metastatic urothelial carcinoma until data from randomised phase III trials of ICIs are available. Level of consensus: 87% Agree, 3% disagree, 10% equivocal (29 voters). Table 2 )
45)
32)
1. In patients with advanced/metastatic urothelial cancer who are ineligible for cisplatin-based therapy but with high PD-L1 expression (as per approved drug-specific methodology), both treatment with an ICI and chemotherapy can be offered Table 2 )
45)
32)
11. Sequencing of different ICIs is indicated when one fails in patients with advanced/metastatic urothelial cancer with progression after platinum-based chemotherapy Table 2 for details of consensus level criteria). Statements indicated in bold were subsequently reviewed at the consensus conference with revised statements and voting shown in Table 12 .
A, agree; D, disagree; E, equivocal; ICI, immune checkpoint inhibitor; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle-invasive bladder cancer; On, Oncologists; PD-L1, programmed death-ligand 1; U, unable to respond; Ur, Urologists.
4. The role of chemotherapy in cisplatin-ineligible, immunotherapy-refractory patients with metastatic urothelial carcinoma.
To the best of our knowledge, there is no evidence that sequencing ICIs in the face of disease progression is of clinical benefit in urothelial carcinoma. The drugs have, at least in part, an overlapping mechanism of action and therefore sequencing of these drugs is counterintuitive [63] . Retrospective data suggest that patients who progress on first-line immunotherapy appear to maintain a reasonable objective RR to a subsequent line of chemotherapy [64] . Thus, sequencing chemotherapy after first-line immunotherapy is attractive whilst we await data from prospective clinical trials.
Statement 4:
Cisplatin-ineligible, immunotherapyrefractory patients with metastatic urothelial carcinoma should be considered for chemotherapy instead of sequencing of immunotherapy. Level of consensus: 81% Agree, 7% disagree, 12% equivocal (27 voters).
Follow-up strategies and survivorship
The Delphi survey included 20 statements relating to follow-up strategies and survivorship after radical cystectomy, trimodality bladder preservation treatment or chemotherapy for urothelial carcinoma (Table 13 ). According to the Delphi survey results, 12 of the 20 statements reached consensus, nine among all stakeholder groups and three among relevant stakeholder groups only (Table 13 ). Of the eight remaining statements, seven were prioritised for further discussion and revision at the consensus conference. Results from the consensus panel scoring of the new/revised statements are shown in Table 14 and supporting text is provided below.
1. Follow-up after radical cystectomy. After cystectomy, depending on the stage (pT and pN), up to 70% of patients will have tumour recurrence which may be local or systemic. There is also a risk of second cancers in the remaining urothelial tract (upper urinary tract tumours and in the urethra). There are no prospective data evaluating the benefit of regular follow-up in patients with urothelial cancer of the bladder after treatment with curative intent versus staging when symptoms occur.
In general, chemotherapy is better tolerated and is associated with more favourable outcomes in patients with a good PS, suggesting that earlier detection of metastases may be beneficial for patients compared with waiting for symptomatic progression. Regular follow-up is recommended in most guidelines despite the lack of high-level evidence. As such, follow-up protocols after cystectomy are mainly based on the natural history of the disease.
Incidence rates and timing of recurrence after cystectomy vary according to the type of recurrence observed. Systemic recurrence occurs in 22%-30% of patients, mostly in the first 3 years, whereas local recurrence occurs in 5%-15% of patients, mostly in the first 2 years and typically between 6 and 18 months [65] [66] [67] . The lifetime incidence of a second cancer in the urethra is 4%-6%, with most diagnosed during the first 3 years, although such cancers have been reported beyond 5-10 years. The lifetime incidence of upper urinary tract tumours is 2%-6%. Here, the median time to diagnosis exceeds 3 years in 70% of cases, indicating that they are typically a late event [65] [66] [67] .
The probability of a systemic or a local recurrence is largely related to the final pathological stage of the cystectomy specimen. The highest likelihood of onset of extravesical recurrence is related to the presence of multifocal disease (a common risk factor), tumour in the distal ureter in the case of upper urinary tract tumours and tumour in the prostatic urethra in men in the case of urethral tumours [67] . In women, where urethrectomy is becoming less common during radical cystectomy, the main risk factors for urethral recurrence are bladder neck and anterior vaginal wall involvement [68] .
According to these recurrence rates, it seems reasonable to apply a more intense follow-up protocol during the first 2-3 years in order to detect systemic relapse after cystectomy Table 2 )
45)
32)
1. After radical cystectomy with curative intent, no regular followup is needed Table 2 )
45)
32)
12. After trimodality treatment with curative intent, NO follow-up imaging to assess distant recurrence or recurrence outside the bladder is needed Table 2 for details of consensus level criteria). Statements indicated in bold were subsequently reviewed at the consensus conference with revised statements and voting shown in with the recommendation to stop follow-up after 5 years for the majority of patients. Those with risk factors of urethral and/or upper urinary tract tumours should, however, be followed up for a longer duration by specific examinations based on their higher risk of a late recurrence. Supplementary Table S1 , available at Annals of Oncology online, shows the follow-up strategies after cystectomy and trimodality bladder preservation treatment according to guidelines issued by ESMO and EAU [3, 5] .
Statement 1:
To detect relapse after radical cystectomy with curative intent, routine imaging with CT of the thorax and abdomen should be stopped after 5 years in the majority of patients. Level of consensus: 88% Agree, 3% disagree, 9% equivocal (32 voters). Statement 2: To detect relapse after radical cystectomy with curative intent, a CT of the thorax and abdomen is recommended as the imaging method for follow-up in the majority of patients. Level of consensus: 94% Agree, 0% disagree, 6% equivocal (34 voters). Statement 3: After radical cystectomy with curative intent, follow-up of the urethra with cytology and/or cystoscopy is recommended in selected patients (e.g. multifocality, carcinoma in situ [CIS] and tumour in the prostatic urethra). Level of consensus: 88% Agree, 6% disagree, 6% equivocal (33 voters).
2. Follow-up after trimodality bladder preservation treatment. Between 26% and 43% of patients treated with trimodality bladder preservation treatment will present with recurrences, which mostly occur within the first 2 years [69] . Follow-up after trimodality bladder preservation treatment must detect not only systemic recurrences but also local and non-muscle-invasive bladder recurrences. Indeed, studies with a longer follow-up protocol mainly use cystoscopy in order to follow patients after the trimodality bladder preservation treatment [70] .
There are no data to show whether regular follow-up after systemic therapy for patients with a partial or complete response is associated with any benefit.
Statement 4:
To detect relapse (outside the bladder) after trimodality treatment with curative intent, CT of the thorax and abdomen is recommended as the imaging method for follow-up in the majority of patients. Level of consensus: 100% Agree (34 voters). Statement 5: To detect relapse (outside the bladder) after trimodality treatment with curative intent, routine imaging with CT of the thorax and abdomen should be stopped after 5 years in the majority of patients. Level of consensus: 84% Agree, 3% disagree, 13% equivocal (30 voters).
3. Follow-up monitoring of carcinoembryonic antigen, LDH and vitamin B12. There is no evidence that any tumour markers are helpful in monitoring recurrence in patients with bladder cancer. LDH is non-specific and can be elevated in a multitude of clinical scenarios independent of a recurrence. Carcinoembryonic antigen (CEA) is also not specific for bladder cancer and can be positive in follow-up as it can be elevated in smokers. Low vitamin B12 levels have been reported in 17% of patients with bowel diversion [71] . Thus, in case of cystectomy and bowel diversion, vitamin B12 levels should be measured. 
Discussion
This international, multi-stakeholder consensus-finding collaborative project was the first of its kind to bring together a large multidisciplinary group of professional medical societies and world-leading experts in the management of advanced and variant bladder cancer with a view to identifying specific situations where guidance is lacking and defining the optimal approach as far as possible based on the available evidence and collective experience and expert opinions. This project resulted in the development of 71 consensus statements that will help to address controversial topics in the management of advanced and variant bladder cancer and can be used to underpin future guideline recommendations. Although too many to discuss here in detail, some key conclusions are worthy of highlighting. For example, as variant histologies are increasingly recognised and diagnosed, our consensus statements in this area are important and provide additional guidance for the management of this group of patients, although not for all variant histologies. In spite of advice from the Food and Drug Administration and EMA, markers are not yet adequate for clinical decision making, including PD-L1 status, (epi)genetic markers and several simple serum measurements. Trimodality bladder preservation treatment with chemoradiation is gaining consensus. It is a multidisciplinary decision where several sensitisers can be used. Modern radiotherapy techniques are preferred, whereas dose escalation and brachytherapy are not. The role of PLND in case of chemoradiation remains unresolved. OMD can still be cured in selected cases, depending on the site and number of metastases and the interval between diagnosis of the primary tumour and metastases. Treatment is a multimodal approach. ICIs are an option in the treatment of metastatic urothelial cancer in unfit, PD-L1-positive patients or after platinum-based chemotherapy. When ICIs are used, pseudo-progression has not been demonstrated in urothelial cancer. When progression occurs on ICI therapy, chemotherapy should be considered rather than sequencing another ICI. Oncological follow-up after cystectomy or bladder preservation should last 5 years, with the highest intensity in the first 2 years as most recurrences occur within 18-24 months. Follow-up should consist of CT of the thorax and abdomen and cystoscopy/cytology in case of bladder preservation.
Taken together, these findings serve to complement existing guidelines and promote a consistent approach to the management of patients with advanced and variant bladder cancer, especially across smaller hospitals where a high level of expert guidance may be lacking.
Although we believe that the methodology applied here is novel and represents an effective approach to obtain a consensus of expert opinion, it is not without its limitations. For example, no systematic literature review was conducted ahead of the Delphi survey and proposed statements were compiled based on the collective expert opinion of the steering committee members. However, as this comprised a group of 13 leading experts, it is unlikely to have resulted in any significant omissions or bias. Another potential limitation was the difference in participants of the Delphi survey versus those who attended the consensus conference. Ideally, this would have comprised the same group of experts; however, based on limited availability of survey participants for a face-to-face meeting, it was felt that additional HCPs should also be invited in order to ensure sufficient collective expertise at the consensus conference.
Regarding the Delphi survey methodology, a potential limitation was the inclusion of an 'equivocal' score in addition to 'unable to score'. On reflection, it is likely that some participants could have scored statements as 'equivocal' when they did not have sufficient expertise to assess the statement rather than selecting 'unable to score', which could have increased the proportion of statements that failed to reach consensus as part of the Delphi survey. We attempted to address this limitation by conducting a second, ad hoc analysis, restricting results to specific stakeholder groups considered to have adequate relevant expertise relating to the specific statement. Indeed, this increased the number of statements achieving consensus from 33 (28%) to 49 (42%). This point was also rectified during the consensus conference with participants advised to refrain from voting in cases of uncertainty or insufficient expertise, and this likely influenced the high level (81%) of consensus achieved.
As with all guidelines, the development of specific statements and recommendations poses a challenge since treatment decisions are typically based on a multitude of parameters unique to the individual patient being treated, with specific parameters rarely considered in isolation. Voting on the level of agreement for each statement is therefore also challenging without a broader clinical context. However, providing such additional information would make statements unwieldy and may also restrict their applicability and use. It is also assumed that the treating physician is able to consider the consensus statements provided and adapt his/her approach in light of the individual clinical context faced.
Conclusions
The results reported here represent a significant achievement by providing collective international expert opinion and guidance on the optimal management strategies to employ in controversial situations until a time where further evidence is available to guide our approach. Together with existing CPGs, it is anticipated that the consensus statements provided here will help to optimise and standardise the diagnosis, treatment and follow-up of patients with advanced and variant bladder cancer. personal fees from Lilly, EMD Serono, Adicet Bio, Inovio, QED Therapeutics, Ranier (Bioclin) Therapeutics, Sensei Biotherapeutics, Chugai Pharma, Western Oncolytics, Pharmacyclics, GSK, Janssen. M Rouprêt: grants/research support from GSK, Pfizer, Roche; honoraria or consultation fees from Lilly, GSK, Ipsen, Astellas, Takeda, Sanofi Pasteur, Medac. O Rouvière: travel expenses from Philips. A Salminen: lecture fee from Roche. P Sargos: grants/research support from Ipsen,
